Want to see IN:JAGSNPHARM full AI Analyst Report?
Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) Ratios
Jagsonpal Pharmaceuticals Ltd. Ratios
IN:JAGSNPHARM's free cash flow for Q1 2027 was $0.00. For the 2027 fiscal year, IN:JAGSNPHARM's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.06 | 6.22 | 10.42 | 5.97 | 4.04 |
| Quick Ratio | 4.54 | 5.64 | 9.63 | 5.22 | 2.94 |
| Cash Ratio | 0.35 | 4.97 | 0.67 | 0.40 | 0.93 |
| Solvency Ratio | 1.30 | 1.66 | 0.81 | 0.77 | 0.54 |
| Operating Cash Flow Ratio | 1.65 | 2.13 | 1.84 | 1.69 | 0.21 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 61.88 | 0.00 |
| Net Current Asset Value | $ 1.03B | $ 1.23B | $ 1.70B | $ 1.29B | $ 714.82M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 |
| Debt-to-Equity Ratio | 0.03 | 0.04 | 0.05 | 0.04 | 0.04 |
| Debt-to-Capital Ratio | 0.03 | 0.04 | 0.05 | 0.04 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 1.16 | 1.16 | 1.23 | 1.29 |
| Debt Service Coverage Ratio | 52.10 | 38.18 | 30.64 | 24.26 | 72.51 |
| Interest Coverage Ratio | 47.31 | 45.46 | 26.29 | 83.18 | 86.12 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.37 | 1.51 | 1.47 | 0.98 | 0.84 |
| Net Debt to EBITDA | -0.03 | -2.34 | -0.12 | -0.14 | -0.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 63.66% | 64.11% | 31.27% | 60.67% | 58.97% |
| EBIT Margin | 20.38% | 15.98% | 14.68% | 14.82% | 12.36% |
| EBITDA Margin | 23.67% | 19.01% | 15.50% | 15.38% | 13.08% |
| Operating Profit Margin | 16.93% | 16.21% | 10.26% | 14.50% | 11.28% |
| Pretax Profit Margin | 20.03% | 26.00% | 14.31% | 14.70% | 12.24% |
| Net Profit Margin | 15.00% | 20.60% | 10.76% | 11.29% | 8.67% |
| Continuous Operations Profit Margin | 15.00% | 20.60% | 10.76% | 11.29% | 8.67% |
| Net Income Per EBT | 74.90% | 79.25% | 75.21% | 76.77% | 70.77% |
| EBT Per EBIT | 118.28% | 160.41% | 139.55% | 101.39% | 108.54% |
| Return on Assets (ROA) | 13.60% | 19.90% | 10.35% | 13.71% | 11.19% |
| Return on Equity (ROE) | 15.60% | 23.07% | 11.99% | 16.82% | 14.41% |
| Return on Capital Employed (ROCE) | 16.86% | 17.26% | 10.81% | 20.51% | 17.35% |
| Return on Invested Capital (ROIC) | 12.56% | 13.59% | 8.08% | 15.60% | 12.43% |
| Return on Tangible Assets | 18.05% | 28.74% | 10.35% | 13.70% | 11.35% |
| Earnings Yield | 3.45% | 3.79% | 2.98% | 3.52% | 2.30% |
| Efficiency Ratios | |||||
| Receivables Turnover | 16.71 | 20.39 | 19.06 | 11.34 | 13.12 |
| Payables Turnover | 9.01 | 9.91 | 14.74 | 11.86 | 5.18 |
| Inventory Turnover | 7.13 | 6.34 | 9.56 | 4.50 | 3.23 |
| Fixed Asset Turnover | 39.08 | 30.41 | 22.44 | 9.75 | 9.73 |
| Asset Turnover | 0.91 | 0.97 | 0.96 | 1.21 | 1.29 |
| Working Capital Turnover Ratio | 2.30 | 1.70 | 1.32 | 2.16 | 2.68 |
| Cash Conversion Cycle | 32.55 | 38.58 | 32.54 | 82.46 | 70.33 |
| Days of Sales Outstanding | 21.85 | 17.90 | 19.15 | 32.18 | 27.83 |
| Days of Inventory Outstanding | 51.21 | 57.53 | 38.16 | 81.06 | 112.96 |
| Days of Payables Outstanding | 40.50 | 36.84 | 24.77 | 30.79 | 70.45 |
| Operating Cycle | 73.05 | 75.43 | 57.31 | 113.24 | 140.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.95 | 8.21 | 5.30 | 7.12 | 0.85 |
| Free Cash Flow Per Share | 6.93 | 8.16 | 5.26 | 7.07 | 0.78 |
| Dividend Paid and CapEx Coverage Ratio | 2.79 | 4.07 | 2.63 | 146.90 | 0.51 |
| Capital Expenditure Coverage Ratio | 316.30 | 158.91 | 141.80 | 146.90 | 11.97 |
| Operating Cash Flow Coverage Ratio | 5.73 | 5.99 | 3.93 | 7.77 | 1.07 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.21 | 0.17 | 0.20 | 0.03 |
| Free Cash Flow Yield | 3.73% | 3.76% | 4.64% | 6.10% | 0.62% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 29.01 | 26.28 | 33.53 | 28.41 | 43.57 |
| Price-to-Sales (P/S) Ratio | 4.35 | 5.44 | 3.61 | 3.21 | 3.78 |
| Price-to-Book (P/B) Ratio | 4.53 | 6.09 | 4.02 | 4.78 | 6.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 26.78 | 26.60 | 21.57 | 16.38 | 160.11 |
| Price-to-Operating Cash Flow Ratio | 26.70 | 26.43 | 21.42 | 16.27 | 146.74 |
| Price-to-Earnings Growth (PEG) Ratio | -1.29 | 0.18 | -2.01 | 0.68 | 4.05 |
| Enterprise Value Multiple | 18.35 | 26.28 | 23.17 | 20.72 | 28.17 |
| Enterprise Value | 12.48B | 13.42B | 7.49B | 7.54B | 8.02B |
| EV to EBITDA | 18.35 | 26.28 | 23.17 | 20.72 | 28.17 |
| EV to Sales | 4.34 | 5.00 | 3.59 | 3.19 | 3.68 |
| EV to Free Cash Flow | 26.74 | 24.43 | 21.46 | 16.28 | 156.23 |
| EV to Operating Cash Flow | 26.66 | 24.27 | 21.31 | 16.17 | 143.18 |
| Tangible Book Value Per Share | 29.45 | 22.92 | 28.23 | 24.26 | 19.62 |
| Shareholders’ Equity Per Share | 41.03 | 35.63 | 28.23 | 24.26 | 19.98 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.21 | 0.25 | 0.23 | 0.29 |
| Revenue Per Share | 42.67 | 39.90 | 31.44 | 36.14 | 33.22 |
| Net Income Per Share | 6.40 | 8.22 | 3.38 | 4.08 | 2.88 |
| Tax Burden | 0.75 | 0.79 | 0.75 | 0.77 | 0.71 |
| Interest Burden | 0.98 | 1.63 | 0.97 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.19 | 0.26 | 0.02 | 0.02 | 0.05 |
| Stock-Based Compensation to Revenue | 0.01 | 0.03 | 0.06 | 0.04 | 0.00 |
| Income Quality | 0.81 | 1.00 | 1.57 | 1.34 | 0.20 |
Currency in INR